Zacks Investment Research on MSN22h
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.
News-Medical.Net1d
Fatty liver disease linked to higher mortality risk from many common diseases
A comprehensive study from Karolinska Institutet shows that people with fatty liver disease have almost twice the mortality ...
RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $90.00.
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval
Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...
Why is Google paying so much for Wiz?
Google’s $32B Wiz acquisition raises questions on strategy, AI competition, and cloud dominance as investors react ...
Zacks Investment Research on MSN5d
GILD Stock Down on Report of Cut in HIV Prevention Spending
Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...
Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention
The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors
Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.